Indaptus Therapeutics to Present at the MedInvest Biotech and Pharma Investor ConferenceGlobe Newswire • 26 days ago
NEW YORK, March 28, 2024 (GLOBE NEWSWIRE) -- Indaptus Therapeutics, Inc. (Nasdaq: INDP), a clinical stage biotechnology company dedicated to pioneering innovative cancer and viral infection...
Share to Feed
Data demonstrates that Company's Decoy platform successfully induces or activates multiple immune cell types involved in anti-tumor responses New data shows activity in M1 macrophages, natural...
Tribe Public Webinar with Indaptus Therapeutics
Tribe Public Webinar with Indaptus Therapeutics
Fully Engaging The Human Immune System To Cure Disease, Featuring CEO, Jeffrey...
Announced Positive Results from Second Cohort of Phase 1 Trial of Decoy20 Initiating Multi-Dosing for patients with solid tumors NEW YORK, March 13, 2024 (GLOBE NEWSWIRE) -- Indaptus...
Indaptus Therapeutics, Inc. (NASDAQ:INDP Get Free Report) saw a large growth in short interest during the month of February. As of February 15th, there was short interest totalling 17,200...
Positive data following completion of second cohort of Phase 1 trial of Decoy 20 leads independent Safety Review Committee to recommend initiating multi-dosing cohort Single dose cohort data...
Gagnants
Le titre Ainos (NASDAQ:AIMD) a mont vendredi de 54,28% 1,62 dollars lors de la session after-market.
Le titre Aadi Bioscience (NASDAQ:AADI) a grimp de 27,60% 2,45 dollars.
Le titre...
NEW YORK, Feb. 15, 2024 (GLOBE NEWSWIRE) -- Indaptus Therapeutics, Inc. (Nasdaq: INDP), a clinical stage biotechnology company dedicated to pioneering innovative cancer and viral infection...
NEW YORK, Feb. 08, 2024 (GLOBE NEWSWIRE) -- Indaptus Therapeutics, Inc. (Nasdaq: INDP), a clinical stage biotechnology company dedicated to pioneering innovative cancer and viral infection...